

Radium-223 ALSYMPCA

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Radium-223 ALSYMPCA

### FINAL SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Genitourinary Cancers  
 Therapeutic Indication: Treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases  
 Experimental Arm: Radium-223 + Best standard of care  
 Control Arm: Best standard of care + placebo

